ASH 2024 | Novel agents in development for the treatment of CML
Simona Soverini, PhD, University of Bologna, Bologna, Italy, comments on promising new molecules in development for the treatment of chronic myeloid leukemia (CML). She highlights two agents currently in Phase I trial, which have the potential to expand the treatment options for patients with CML. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Actually, we are in a very interesting era again for chronic myeloid leukemia because after many years of nothing on the horizon, we have several new molecules coming out for patients who become resistant. I would like in particular to highlight two interesting molecules that are currently in Phase I clinical trials, but are very interesting. One is from Terns, and it’s another allosteric inhibitor, just acting like a asciminib...
Actually, we are in a very interesting era again for chronic myeloid leukemia because after many years of nothing on the horizon, we have several new molecules coming out for patients who become resistant. I would like in particular to highlight two interesting molecules that are currently in Phase I clinical trials, but are very interesting. One is from Terns, and it’s another allosteric inhibitor, just acting like a asciminib. It’s very interesting because we have been learning the power of allosteric inhibition conjugated with a very limited toxicity profile. So it will be another interesting molecule to be assessed and probably to be added to our armamentarium. And another interesting molecule is from Enliven, another company that has developed a molecule that works a little bit like ponatinib. So it’s an ATP competitive inhibitor, very active against the T315I. So these are two complementary molecules in a way. And I will keep an eye on both these trials because we are still in Phase I, but it will be interesting to see whether these molecules make it all the way to the clinic. We still need more drugs in CML.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Blueprint Medicines: Honoraria; Incyte Biosciences: Consultancy; Istituto Gentili: Honoraria, Research Funding.
